Urogenital cancers, including prostate, kidney, and bladder cancer, remain a significant clinical challenge due to their high incidence, molecular heterogeneity, and frequent resistance to standard therapies. Despite progress in genomic profiling and precision... ...

请注册登录后继续浏览